N-isopropyl-N-methyltrifluoroacetamide | 18263-89-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-isopropyl-N-methyltrifluoroacetamide
• 英文别名: N-Methyl-N-isopropyl-trifluoracetamid；N-Methyl-N-2-propyltrifluoracetamid；2,2,2-trifluoro-N-methyl-N-propan-2-ylacetamide
• CAS: 18263-89-3
• 化学式: C₆H₁₀F₃NO
• 分子量: 169.147
• InChiKey: RJGMNKYZPDMFOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-异丙基甲胺 、 三氟乙酸酐 生成 N-isopropyl-N-methyltrifluoroacetamide
  参考文献：
  名称：

  Gas-Phase ¹H NMR Studies of Internal Rotation Activation Energies and Conformer Stabilities of Asymmetric N,N-Disubstituted Formamides and Trifluoroacetamides

  摘要：

  Activation parameters and conformational stabilities characterizing the internal rotation about the peptide bond in a series of N,N-asymmetric dialkylformamides (HCONR1R2: R-1 = CH3, R-2 = propyl, butyl, and isopropyl) and N,N-asymmetric dialkyltrifluoroacetamides (F3CCONR1R2: R-1 = CH3, R-2 = propyl, butyl, and isopropyl) are determined from temperature-dependent gas-phase H-1 NMR spectra. Conformer free energy differences, Delta G(298)(0)(syn-anti), in cal mol(-1), and activation free energies, Delta G(298)(double dagger), in kcal mol(-1), for the formamides are -83(14)/19.4(0.1) for R-2 = Propyl, -80(14)/19.3(0.1) for R-2 = butyl, and -91(13)/19.1(0.1) for R-2 = isopropyl and for the trifluoroacetamides 178(24)/16.8(0.1) for R-2 = propyl, 191(53)/16.6(0.1) for R-2 = butyl, and 218(29)/16.3(0.1) for R-2 = isopropyl. The preferred conformer in both the gas and Liquid phases has the N-methyl group syn to the carbonyl oxygen in the formamide systems and the N-methyl group anti to the carbonyl oxygen in the trifluoroacetamides. The gas-phase results are compared to liquid-phase values.

  DOI：

  10.1021/jp9734080

文献信息

• HIV REPLICATION INHIBITOR
  申请人：Shionogi & Co., Ltd.

  公开号：US20140249306A1

  公开（公告）日：2014-09-04

  The present invention provides a novel compound having an antiviral action, in particular, an HIV replication inhibiting action, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein, a broken line means the presence or absence of a bond; R 1 is substituted or unsubstituted alkyl etc., R 2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R 3 is a substituted or unsubstituted aromatic carbocyclic group; R 4 is a hydrogen atom etc.; R 5 is a substituted or unsubstituted aromatic carbocyclic group etc.; Y is a single bond etc.; R 6 is substituted or unsubstituted alkyl; R 7 is —Z—R 71 etc.; Z is —NR 72 —CO— etc.; R 71 is substituted or unsubstituted alkyl etc.; R 72 is a hydrogen atom etc.

  本发明提供了一种具有抗病毒作用的新化合物，特别是具有抑制HIV复制作用的化合物，以及一种药物组合物，特别是一种抗HIV药物。其中，虚线表示键的存在或不存在；R1是取代或未取代的烷基等，R2是取代或未取代的烷氧基等；n为1或2；R3是取代或未取代的芳香环烷基；R4是氢原子等；R5是取代或未取代的芳香环烷基等；Y是单键等；R6是取代或未取代的烷基；R7是—Z—R71等；Z是—NR72—CO—等；R71是取代或未取代的烷基等；R72是氢原子等。
• [EN] PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ PYRIMIDINE CARBOXAMIDE ET SON APPLICATION<br/>[ZH] 一种嘧啶甲酰胺类化合物及其应用
  申请人：[en]SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD;[zh]上海美悦生物科技发展有限公司

  公开号：WO2022063197A1

  公开（公告）日：2022-03-31

  本发明公开了一种嘧啶甲酰胺类化合物及其应用。本发明提供了一种如式(I)所示的嘧啶甲酰胺类化合物、或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式或其药学上可接受的盐；其可以用作Vanin酶抑制剂；其可用于制备用于治疗多种病状，包括克罗恩氏病及溃疡性结肠炎等的药物。
• [EN] PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ DE PYRIMIDINE CARBOXAMIDE ET SON UTILISATION<br/>[ZH] 一种嘧啶甲酰胺类化合物及其应用
  申请人：[en]SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD;[zh]上海美悦生物科技发展有限公司

  公开号：WO2022063333A1

  公开（公告）日：2022-03-31

  本发明公开了一种嘧啶甲酰胺类化合物及其应用。本发明提供了一种如式（I）所示的嘧啶甲酰胺类化合物、或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式或其药学上可接受的盐；其可以用作Vanin酶抑制剂；其可用于制备用于治疗多种病状，包括克罗恩氏病及溃疡性结肠炎等的药物。
• US9199959B2
  申请人：——

  公开号：US9199959B2

  公开（公告）日：2015-12-01
• Gas-Phase ¹H NMR Studies of Internal Rotation Activation Energies and Conformer Stabilities of Asymmetric <i>N,N</i>-Disubstituted Formamides and Trifluoroacetamides
  作者：A. N. Taha、S. M. Neugebauer Crawford、N. S. True

  DOI：10.1021/jp9734080

  日期：1998.2.1

  Activation parameters and conformational stabilities characterizing the internal rotation about the peptide bond in a series of N,N-asymmetric dialkylformamides (HCONR1R2: R-1 = CH3, R-2 = propyl, butyl, and isopropyl) and N,N-asymmetric dialkyltrifluoroacetamides (F3CCONR1R2: R-1 = CH3, R-2 = propyl, butyl, and isopropyl) are determined from temperature-dependent gas-phase H-1 NMR spectra. Conformer free energy differences, Delta G(298)(0)(syn-anti), in cal mol(-1), and activation free energies, Delta G(298)(double dagger), in kcal mol(-1), for the formamides are -83(14)/19.4(0.1) for R-2 = Propyl, -80(14)/19.3(0.1) for R-2 = butyl, and -91(13)/19.1(0.1) for R-2 = isopropyl and for the trifluoroacetamides 178(24)/16.8(0.1) for R-2 = propyl, 191(53)/16.6(0.1) for R-2 = butyl, and 218(29)/16.3(0.1) for R-2 = isopropyl. The preferred conformer in both the gas and Liquid phases has the N-methyl group syn to the carbonyl oxygen in the formamide systems and the N-methyl group anti to the carbonyl oxygen in the trifluoroacetamides. The gas-phase results are compared to liquid-phase values.